TM Editors' Note: This article discusses penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.

41 psychedelic drug stocks trade on the various North American stock exchanges and so far this week 21 have gone up, 11 have gone down and 9 have had no change in price. 

Chris Thompson, President and Director of Equity Research at eResearch  Corporation, the new parent company of munKNEE.com, reports research has shown that the psychedelic drugs market:

• is growing with a CAGR of 16.3% between 2020 and 2027 and
• is expected to reach $10.7 billion by 2027 from $2.1 billion in 2019. 

The 41 stocks consist of:

• 7 micro-cap stocks (Group #1) with an average market capitalization of $197M,
• 2 small-cap stocks (Group #2) with an average market capitalization of $1.2B,
• 32 nano-cap stocks (Group #3) with an average market capitalization of just $33M.

Below is the stock price performance for each Group for the 3 days ending April 28th and month-to-date shown in brackets:

The 7 stocks in Group #1:

• have market capitalizations ranging from $104M to $315M and average $197M,
• have advanced 6.2% so far this week (+20.1% so far in April) and
• are constituents in the munKNEE Pure-Play Psychedelic Drug Stocks Index as their market capitalizations are more than $100M and less than $1B.

The performance of the Group #1 constituents so far this week are, in descending order (month-to-date in brackets), as follows :

1. Cybin (CLXPF): +27.6% (+47.3%) to $1.62/share
   • Demonstrated Proof of Concept for its deuterated tryptamine programs, CYB003 and CYB004, for the treatment of Alcohol Use Disorder that affects approximately 5.8% of adults (14.4 million adults - 9.2 million men and 5.3 million women) in the United States ages 18 and older.
2. Field Trip (FTRPF): +11.1% (+7.7%) to $4.92/share
   • No noteworthy news.
3. Bionomics (BNOEF): +5.6% (+5.6%) to $0.19/share
   • Completed a 1 for 6 pro rata non–renounceable entitlement offer that raised approximately A$20.4M,
   •  Novamind Inc. increased its strategic investment in Bionomics Limited to A$1,792,886 with the purchase an additional 951,133 common shares at AU$0.145 per share in Bionomics' recently completed rights offering. 
4. Revive (RVVTF): +2.7% (N/C) @ $0.38/share
   • Filed an application with the U.S. Food and Drug Administration to receive Orphan Drug Designation for psilocybin to treat moderate to severe traumatic brain injury (approximately 50% of people with severe TBI experience further decline in their daily lives or die within 9 years of their injury and are 50x more likely to die from seizures and 6x more likely to die from pneumonia) which would qualify psilocybin for certain benefits and incentives, including seven (7) years of marketing exclusivity upon approval,
   • Applied for a U.S. provisional patent with The United States Patent and Trademark Office on an oral thin-film delivery system with psilocybin for the potential treatment of mental illness and neurological and substance abuse disorders.
5. Numinus (LKYSF): +2.3% (+6.0%) to $0.88/share
   • Announced that the TSX Venture Exchange had accepted its 16.1M common share purchase warrants for listing under the symbol NUMI.WT.C which will entitle the holder to acquire one common share at an exercise price of $1.75 until March 19, 2023.
6. Seelos (SEEL): +1.1% (+47.7%) to $6.32/share
   • Received a positive opinion on European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency Committee for Orphan Medicinal Products,
   • BTIG analyst Bert Hazlett is reiterating his buy recommendation and $14 price target,
   • Signed an agreement with AptarGroup, Inc. for the co-exclusive use and supply of Aptar Pharma's Bidose Liquid System device for Seelos' intranasal ketamine product candidate, SLS-002, in the investigational development programs for the treatment of suicidality, depression, and PTSD.
7. Jaguar (JAGX): -1.2% (+19.4%) to $1.60/share
   • Entered into a securities purchase agreement with North American institutional investors for the purchase and sale of 7,647,000 shares of common stock for gross proceeds of approximately $10.8 million in a registered direct offering for the benefit of the Company's wholly-owned Italian subsidiary, Napo EU S.p.A. 
   • Announced the upsizing by $15.3 million the at-the-market financing program with Ladenburg Thalmann & Co. Inc. for potential future financing needs,
   • Amended its Equity Purchase Agreement with Oasis Capital to purchase up to an aggregate of $2.0 million of Jaguar common stock over a 36-month period at a price of $0.436 to $3.00 and, in consideration of Oasis Capital's agreement, will issue to Oasis Capital a common stock purchase warrant to purchase 100,000 shares of the Company's common stock at a par value $0.0001 per share.

The two stocks in Group #2:

• have market capitalizations of $920M and $1.4B,
• have advanced 7.7% so far this week (+12.2% so far in April) as follows: 

1. Mind Medicine (MMEDF): +37.5% (+94.4%) to $4.84/share
   • Began trading on The Nasdaq Capital Market on April 27, 2021 , under the symbol MNMD in addition to its listing on the Neo Exchange under the symbol MMED. 
2. Compass Pathways (CMPS): +4.7% (+6.4%) to $36.96/share
   • Announced the pricing of its public offering of 4M American Depositary Shares (ADS), representing 4M ordinary shares, at $36.00 per ADS for total gross proceeds of $144.0 million,

The above two stocks are not eligible for inclusion in the Pure-Play Psychedelic Drug Stocks Index as their market capitalizations are so large that their inclusion would skew the performance results of the index so are reported above separately.

The 32 stocks in Group #3:

• have market capitalizations ranging from just $3M to $75M and average $33M,
• have advanced 3.1% so far this week (-1.6% so far in April) with 13 going up in price, 10 going down, and 9 having no change in price and are, in alphabetical order, as follows:
  • Aion, Algernon, Bright Minds, Champignon, Codebase, Core One, Ehave, Entheon, Graph Blockchain, Havn, Hollister, Lobe Sciences, M2BIO, Mind Cure, Mindset, Mydecine,  Neonmind, Newscope-PharmaTher, New Wave, Nova Mentis, Novamind,  Nutritional High, Optimi, PayBio, Psyched Wellness, Pysence, Pure Extracts, Red Light, Silo Wellness, SILO Pharma, Tryp and Thoughtful Brands.

Of the 32 stocks above, the greatest increases so far this week have been in Novamind (+37.6%), Aion (+32.0%) and Thoughtful Brands (+17.4%) and the stocks that have declined the most so far this week are Ehave (-28.6%), Entheon (-11.6%) and Psyched Wellness (-11.1%). 

The above 32 stocks are not eligible for inclusion in our Pure-Play Psychedelic Drug Stocks Index as their market capitalizations are less than $100M.

In Summary

• The 7 stocks in Group #1 have market capitalizations ranging from $104M to $315M (an average $197M) and they have advanced 6.2% so far this week and are +20.1% so far in April.
• The two stocks in Group #2 have market capitalizations of $920M and $1.4B and they have advanced 7.7% so far this week and are +12.2% so far in April.
• The 32 stocks in Group #3 have market capitalizations ranging from just $2M to $70M (an average $33M) and they have advanced 3.1% so far this week and are -1.6% so far in April.

(For more information on the reason(s) behind the changes outlined below you are urged to click on the stock symbols provided by TalkMarkets, where additional information is provided. All currency amounts are in U.S. dollars. Go here to convert to another currency.)